# Zydus Therapeutics Presents Phase 2b Data at AASLD 2026 Showing Greater Resolution of Steatohepatitis Without Worsening of Fibrosis With Investigational Saroglitazar Compared to Placebo in Adults…

- Source: PR Newswire M&A
- Published: 2026-11-06T16:17:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/zydus-therapeutics-presents-phase-2b-data-at-aasld-2026-showing-greater-resolution-of-steatohepatitis-without-worsening-of-fibrosis-with-investigational-saroglitazar-compared-to-placebo-in-adults-with-mash-and-fibrosis-302932179.html
- Canonical: https://groundlevelnews.com/story/zydus-therapeutics-presents-phase-2b-data-at-aasld-2026-showing-greate-70594a/

Resolution of steatohepatitis without worsening of fibrosis was achieved by 39.1% of patients receiving saroglitazar magnesium 4 mg and 32.4% receiving 2 mg, compared with 13.7% receiving placebo, after 52 weeks of treatment in adults with metabolic dysfunction-associated steatohepatitis...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._